PragmaTIL (101104684)

  https://cordis.europa.eu/project/id/101104684

  Horizon Europe (2021-2027)

  Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors

  Pragmatic clinical trials to optimise treatments for patients with refractory cancers (HORIZON-MISS-2022-CANCER-01-03)

  oncology  ·  health economics  ·  cells technologies

  2023-04-01 Start Date (YY-MM-DD)

  2028-03-31 End Date (YY-MM-DD)

  € 5,998,839


  Description

"The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy. This improved tolerability will achieve a better clinical management of patients and enhance their quality of life, both of which represent major barriers for applying this treatment. The objectives of PragmaTIL are: i) To determine whether TIL-ACT using IL-2 analog ANV419 reduces the frequency of Grade 2-4 study-related non-hematological toxicities; ii) To compare the quality of life (QoL) of patients during their hospitalization period, using ANV419 vs HD-IL-2. Also, to compare short and long-term measurements of treatment-related toxicities and QoL co-defined by and for patients and their caregivers; and iii) To develop the health technology assessment (HTA) of TIL-ACT using ANV419, as well as a social return of investment (SROI) analysis. To achieve these objectives, the PragmaTIL project is structured into 6 WP that cover all the requirements to implement the project: WP1) Clinical Trial; WP2) IMPD Coordination, RA and Pharmacovigilance; WP3) Patients as co-researchers and Evaluation of Short- and Long-term PROs; WP4) Health Economics; WP5) SROI, Sustainability and Exploitation; WP6) Scientific Coordination, Project Management, Communication and Dissemination. The global impact of this project will not only reach patients, clinical and translational researchers and policy makers but may help to achieve a better acceptance of these therapies by society at large. This action is part of the Cancer Mission cluster of projects on ""Diagnosis and treatment""."


  Complicit Organisations

1 Israeli organisation participates in PragmaTIL.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Denmark REGION HOVEDSTADEN (999654744) DK30113721 participant PUB € 882,781 € 882,781 € 882,781
Spain FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO) (995163935) ESG64384969 coordinator REC € 1,103,573 € 1,103,573 € 730,603
France INSTITUT GUSTAVE ROUSSY (999454924) FR91775741101 participant REC € 219,375 € 219,375 € 219,375
Spain BANC DE SANG I TEIXITS (996252081) ESQ5856387E thirdParty REC € 0 € 0 € 372,970
France UNICANCER (952728375) nan participant REC € 319,375 € 319,375 € 319,375
France CITOYENS ET RECHERCHE (885271568) FR93828537167 participant PRC € 169,375 € 169,375 € 169,375
Israel MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER (998129904) nan participant REC € 912,968 € 912,968 € 912,968
Spain FUNDACION BANCARIA CAIXA D'ESTALVIS I PENSIONS DE BARCELONA LA CAIXA (998954404) ESG58899998 participant OTH € 111,718 € 111,718 € 111,718
Spain BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL (908584063) ESB64392350 participant PRC € 198,125 € 198,125 € 198,125
Netherlands STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (999984738) NL002562169B01 participant REC € 912,968 € 912,968 € 912,968
Spain INNOVANDUM HEALTH SL (917632708) ESB98768542 participant PRC € 88,235 € 88,235 € 88,235
Spain ASPHALION SL (951218473) ESB62497276 participant PRC € 168,125 € 168,125 € 168,125
Sweden REGION STOCKHOLM (999522921) SE232100001601 participant PUB € 912,218 € 912,218 € 912,218